This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
by Zacks Equity Research
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
Philips (PHG) Showcases New AI-Based Solutions at the RSNA
by Zacks Equity Research
Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
by Zacks Equity Research
Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.
Philips (PHG) Expands Partnership to Build Angio CT Solution
by Zacks Equity Research
Philips (PHG) is building the world's first spectral detector angio CT solution by forging an alliance with the Leiden University Medical Center.
Philips (PHG) Alerts Users of Health Hazards of Therapy Masks
by Zacks Equity Research
Philips (PHG) cautions customers against health hazards faced by the users of CPAP or Bi-Level PAP therapy masks with magnetic headgear.
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.
Philips (PHG) Expands AI Portfolio With SmartSpeed Solution
by Zacks Equity Research
Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant
by Zacks Equity Research
Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
by Zacks Equity Research
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug
by Zacks Equity Research
Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.